EdgeMarket › What Paradigm Biocapital Advisors Lp reported owning
What Paradigm Biocapital Advisors Lp reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
4.9BPositions
35Quarter
2026-03-31Shown below
35largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| unmapped CUSIP 03940C100 | 663.0M | 13.5% | 5.8M | — | — |
| RVMD Revolution Medicines, Inc. | 647.3M | 13.2% | 6.7M | 209.46 | +479.3% |
| unmapped CUSIP 670703107 | 545.5M | 11.1% | 5.3M | — | — |
| PCVX Vaxcyte, Inc. | 278.5M | 5.7% | 4.8M | 62.62 | +100.3% |
| EWTX Edgewise Therapeutics, Inc. | 232.0M | 4.7% | 7.4M | 44.18 | +219.2% |
| GMAB GENMAB A/S | 213.8M | 4.4% | 8.0M | 33.45 | +39.0% |
| INSM INSMED Inc | 205.1M | 4.2% | 1.3M | 125.77 | -2.8% |
| TARS Tarsus Pharmaceuticals, Inc. | 179.7M | 3.7% | 2.6M | 72.70 | +31.2% |
| BLTE BELITE BIO, INC | 177.7M | 3.6% | 1.1M | 161.06 | +154.0% |
| ERAS Erasca, Inc. | 168.2M | 3.4% | 10.4M | 17.63 | +1107.5% |
| unmapped CUSIP 152309100 | 142.0M | 2.9% | 3.6M | — | — |
| OLMA Olema Pharmaceuticals, Inc. | 119.6M | 2.4% | 8.0M | 10.69 | +96.1% |
| unmapped CUSIP 880881107 | 116.9M | 2.4% | 2.2M | — | — |
| ORKA Oruka Therapeutics, Inc. | 113.8M | 2.3% | 2.3M | 107.96 | +649.7% |
| APGE Apogee Therapeutics, Inc. | 113.5M | 2.3% | 1.3M | 134.75 | +274.1% |
| SYRE Spyre Therapeutics, Inc. | 98.7M | 2.0% | 2.0M | 106.49 | +551.3% |
| CYTK CYTOKINETICS INC | 97.6M | 2.0% | 1.5M | 76.84 | +105.9% |
| ABVX Abivax S.A. | 86.0M | 1.8% | 772.5K | 114.95 | +59.9% |
| TNGX Tango Therapeutics, Inc. | 83.9M | 1.7% | 4.0M | 23.88 | +253.8% |
| MAZE Maze Therapeutics, Inc. | 81.9M | 1.7% | 2.7M | 29.43 | +118.3% |
| TYRA Tyra Biosciences, Inc. | 78.7M | 1.6% | 2.1M | 26.05 | +154.4% |
| VRDN Viridian Therapeutics, Inc.\DE | 61.6M | 1.3% | 3.1M | 24.29 | +33.9% |
| SRRK Scholar Rock Holding Corp | 60.3M | 1.2% | 1.2M | 56.50 | +64.2% |
| MIRM Mirum Pharmaceuticals, Inc. | 57.7M | 1.2% | 625.0K | 96.31 | +44.4% |
| EYPT EyePoint, Inc. | 40.5M | 0.8% | 3.1M | 5.32 | -53.8% |
| LXEO Lexeo Therapeutics, Inc. | 35.5M | 0.7% | 6.2M | 4.88 | +1.7% |
| MANE Veradermics, Inc | 33.2M | 0.7% | 525.0K | 102.82 | — |
| VOR Vor Biopharma Inc. | 31.2M | 0.6% | 1.8M | 23.36 | -46.9% |
| URGN UroGen Pharma Ltd. | 30.6M | 0.6% | 1.7M | 46.86 | +142.7% |
| GPCR Structure Therapeutics Inc. | 26.3M | 0.5% | 545.3K | 49.09 | +164.4% |
| IVA Inventiva S.A. | 22.2M | 0.5% | 4.0M | 4.68 | +2.2% |
| ORIC Oric Pharmaceuticals, Inc. | 21.6M | 0.4% | 1.7M | 14.20 | +49.3% |
| ASMB ASSEMBLY BIOSCIENCES, INC. | 18.5M | 0.4% | 665.3K | 34.38 | +31.5% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 7.8M | 0.2% | 868.2K | 9.08 | -5.7% |
| KLRS Kalaris Therapeutics, Inc. | 4.0M | 0.1% | 700.0K | 4.15 | +61.5% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →